Suven Life Sciences Ltd (Suven) announces today that the grant of one (1) product patent from India (285812) and one (1) product patent from Japan (6185650) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2027 and 2032 respectively.
The granted claims of the patents include the class of selective 5-HT compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.
Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.176.1 as compared to the previous close of Rs. 183.85. The total number of shares traded during the day was 126697 in over 2041 trades.
The stock hit an intraday high of Rs. 184.4 and intraday low of 171.55. The net turnover during the day was Rs. 22406752.